6:44 PM
 | 
Dec 13, 2011
 |  BC Extra  |  Clinical News

Actelion decides not to buy Trophos after Phase III miss

Actelion Ltd. (SIX:ATLN) said it will not exercise an option to acquire Trophos S.A. (Marseille, France) for between EUR 125-EUR 195 million ($166.4-$259.6 million) after Trophos' olesoxime missed the primary endpoint in a Phase...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >